This week, we’ll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we’ll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we’ll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.

Coverage of stories discussed this week on ascopost.com:

Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer

Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease